Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018
April 23, 2018 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., April 23, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and...
Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
January 03, 2018 16:30 ET
|
Zynerba Pharmaceuticals, Inc.
- Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30...
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
September 28, 2017 06:30 ET
|
Zynerba Pharmaceuticals, Inc.
ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa., Sept. 28, 2017 ...